Ultrasound Verification of Plaque Brachytherapy Placement in Patients Treated for Primary Uveal Melanoma: A Single-Center Experience.

IF 0.9 Q4 OPHTHALMOLOGY
Ocular Oncology and Pathology Pub Date : 2023-08-01 Epub Date: 2023-03-14 DOI:10.1159/000529836
Joseph M Grimes, Henry Zhou, Alexis K Dal Col, Alexandra Gershkovich, Dmitry Bogomolny, Brian P Marr
{"title":"Ultrasound Verification of Plaque Brachytherapy Placement in Patients Treated for Primary Uveal Melanoma: A Single-Center Experience.","authors":"Joseph M Grimes, Henry Zhou, Alexis K Dal Col, Alexandra Gershkovich, Dmitry Bogomolny, Brian P Marr","doi":"10.1159/000529836","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Proper plaque positioning is essential for effective episcleral plaque brachytherapy and can be verified using ultrasound. In this study, we show our center's protocol for intraoperative ultrasound verification of plaque placement and present our single-center local recurrence data in patients with primary UM involving the choroid and/or ciliary body. We also indicate our center's distance metastasis rate for patients presenting with primary UM.</p><p><strong>Methods: </strong>All patients who presented to our institution with UM of the choroid and/or ciliary body between May 2017 and March 2022 and treated with plaque brachytherapy were enrolled. Endpoints include the 24-month local recurrence-free rate (primary) and 24-month metastasis rate (secondary), both estimated using the Kaplan-Meier method (KM).</p><p><strong>Results: </strong>Local Recurrence: 176 patients met the study criteria with median follow-up of 23.2 months. The 24-month recurrence-free probability for this cohort was estimated at 99.1% (95% confidence interval: 0.974-1.00). Metastatic Recurrence: 136 of these patients underwent at least one follow-up surveillance scan. The 24-month metastasis-free survival probability in our cohort was estimated at 87% (95% confidence interval: 81-94%).</p><p><strong>Conclusions: </strong>We show improved local control utilizing ultrasound verification compared to historical controls who received TTT and brachytherapy without intraoperative ultrasound confirmation.</p>","PeriodicalId":19434,"journal":{"name":"Ocular Oncology and Pathology","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10821787/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ocular Oncology and Pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000529836","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/3/14 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Proper plaque positioning is essential for effective episcleral plaque brachytherapy and can be verified using ultrasound. In this study, we show our center's protocol for intraoperative ultrasound verification of plaque placement and present our single-center local recurrence data in patients with primary UM involving the choroid and/or ciliary body. We also indicate our center's distance metastasis rate for patients presenting with primary UM.

Methods: All patients who presented to our institution with UM of the choroid and/or ciliary body between May 2017 and March 2022 and treated with plaque brachytherapy were enrolled. Endpoints include the 24-month local recurrence-free rate (primary) and 24-month metastasis rate (secondary), both estimated using the Kaplan-Meier method (KM).

Results: Local Recurrence: 176 patients met the study criteria with median follow-up of 23.2 months. The 24-month recurrence-free probability for this cohort was estimated at 99.1% (95% confidence interval: 0.974-1.00). Metastatic Recurrence: 136 of these patients underwent at least one follow-up surveillance scan. The 24-month metastasis-free survival probability in our cohort was estimated at 87% (95% confidence interval: 81-94%).

Conclusions: We show improved local control utilizing ultrasound verification compared to historical controls who received TTT and brachytherapy without intraoperative ultrasound confirmation.

超声波验证原发性葡萄膜黑色素瘤患者的斑块近距离放射治疗位置:单中心经验。
介绍:正确的斑块定位对有效的巩膜外斑块近距离放射治疗至关重要,可通过超声波进行验证。在本研究中,我们展示了本中心的术中超声检查斑块位置的方案,并介绍了我们单中心对脉络膜和/或睫状体受累的原发性UM患者的局部复发数据。我们还指出了本中心原发性 UM 患者的远处转移率:所有在2017年5月至2022年3月期间到我院就诊的脉络膜和/或睫状体UM患者均接受了斑块近距离放射治疗。终点包括24个月无局部复发率(原发性)和24个月转移率(继发性),均采用卡普兰-梅耶法(KM)估算:局部复发:176名患者符合研究标准,中位随访时间为23.2个月。该组患者 24 个月无复发的概率估计为 99.1%(95% 置信区间:0.974-1.00)。转移性复发:这些患者中有 136 人接受了至少一次随访监测扫描。我们队列中的 24 个月无转移生存概率估计为 87%(95% 置信区间:81-94%):与未接受术中超声确认的 TTT 和近距离放射治疗的历史对照组相比,我们的研究结果表明,利用超声验证提高了局部控制率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.40
自引率
0.00%
发文量
20
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信